ArticleCardiovascular & hematological disorders drug targets2022
Antihyperglycemic and Antidyslipidemic Effect of
Article in Cardiovascular & hematological disorders drug targets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
aimsThe present work aimed to assess the antihyperglycemic and antihyperlipidemic effects of Moricandia suffruticosa.
backgroundMoricandia suffruticosa (M. suffruticosa) is used in traditional medicine.
objectiveThe present study investigated the antihyperglycemic and antidyslipidemic effects of M. suffruticosa and its effect on glycogen content in normoglycemic and hyperglycemic rats.
methodsThe effect of the aqueous extract of M. suffruticosa (AEMS) at two doses of 100 and 140 mg/kg on blood glucose levels, lipid, lipoprotein profile, and glycogen content was examined in normal and streptozotocin (STZ)-induced diabetic rats. Moreover, preliminary phytochemical screening and quantification of phenolic, flavonoid, and tannin contents were carried out.
resultsThe results demonstrated that AEMS exhibits antihyperglycemic activity in diabetic rats during both acute and subchronic assays. Furthermore, AEMS revealed an antidyslipidemic effect concerning the level of triglycerides, total cholesterol, very-low-density lipoprotein (VLDL), and non-high-density lipoproteins (Non-HDL). In contrast, AEMS has not affected the value of glycemia, lipids, and lipoproteins in normal rats. In addition, AEMS is rich in several phytochemical compounds. Furthermore, AEMS revealed an important in vitro antioxidant activity.
conclusionIn conclusion, the study demonstrates that M. suffruticosa exhibits an important antihyperglycemic effect in diabetic rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.